167 related articles for article (PubMed ID: 35978496)
1. Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs.
Qin Q; Wang R; Fu Q; Zhang G; Wu T; Liu N; Lv R; Yin W; Sun Y; Sun Y; Zhao D; Cheng M
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2241-2255. PubMed ID: 35978496
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: Design, synthesis, and biological study.
Sun Y; Wang R; Sun Y; Wang L; Xue Y; Wang J; Wu T; Yin W; Qin Q; Sun Y; Zhao D; Cheng M
Eur J Med Chem; 2022 Jul; 237():114373. PubMed ID: 35486993
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs.
Gao H; Wu Y; Sun Y; Yang Y; Zhou G; Rao Y
ACS Med Chem Lett; 2020 Oct; 11(10):1855-1862. PubMed ID: 33062164
[TBL] [Abstract][Full Text] [Related]
4. Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders.
Yang M; Xiang H; Luo G
Biochem Pharmacol; 2024 Jun; 224():116246. PubMed ID: 38685282
[TBL] [Abstract][Full Text] [Related]
5. Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity.
Koide E; Mohardt ML; Doctor ZM; Yang A; Hao M; Donovan KA; Kuismi CC; Nelson AJ; Abell K; Aguiar M; Che J; Stokes MP; Zhang T; Aguirre AJ; Fischer ES; Gray NS; Jiang B; Nabet B
Chembiochem; 2023 Oct; 24(19):e202300141. PubMed ID: 37088717
[TBL] [Abstract][Full Text] [Related]
6. Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACs.
Law RP; Nunes J; Chung CW; Bantscheff M; Buda K; Dai H; Evans JP; Flinders A; Klimaszewska D; Lewis AJ; Muelbaier M; Scott-Stevens P; Stacey P; Tame CJ; Watt GF; Zinn N; Queisser MA; Harling JD; Benowitz AB
Angew Chem Int Ed Engl; 2021 Oct; 60(43):23327-23334. PubMed ID: 34416073
[TBL] [Abstract][Full Text] [Related]
7. Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation.
Cromm PM; Samarasinghe KTG; Hines J; Crews CM
J Am Chem Soc; 2018 Dec; 140(49):17019-17026. PubMed ID: 30444612
[TBL] [Abstract][Full Text] [Related]
8. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
Lu Y; Sun H
J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, biological evaluation, and molecular dynamics (MD) simulation studies of three novel F-18 labeled and focal adhesion kinase (FAK) targeted 5-bromo pyrimidines as radiotracers for tumor.
Fang Y; Wang D; Xu X; Liu J; Wu A; Li X; Xue Q; Wang H; Wang H; Zhang H
Eur J Med Chem; 2017 Feb; 127():493-508. PubMed ID: 28109944
[TBL] [Abstract][Full Text] [Related]
10. Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy.
Pang XJ; Liu XJ; Liu Y; Liu WB; Li YR; Yu GX; Tian XY; Zhang YB; Song J; Jin CY; Zhang SY
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299525
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine phosphorylation of growth factor receptor-bound protein-7 by focal adhesion kinase in the regulation of cell migration, proliferation, and tumorigenesis.
Chu PY; Huang LY; Hsu CH; Liang CC; Guan JL; Hung TH; Shen TL
J Biol Chem; 2009 Jul; 284(30):20215-26. PubMed ID: 19473962
[TBL] [Abstract][Full Text] [Related]
12. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
13. Focal adhesion kinase inhibitors are potent anti-angiogenic agents.
Cabrita MA; Jones LM; Quizi JL; Sabourin LA; McKay BC; Addison CL
Mol Oncol; 2011 Dec; 5(6):517-26. PubMed ID: 22075057
[TBL] [Abstract][Full Text] [Related]
14. Staurosporine induces endothelial cell apoptosis via focal adhesion kinase dephosphorylation and focal adhesion disassembly independent of focal adhesion kinase proteolysis.
Kabir J; Lobo M; Zachary I
Biochem J; 2002 Oct; 367(Pt 1):145-55. PubMed ID: 12084011
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
Wang R; Chen Y; Zhao X; Yu S; Yang B; Wu T; Guo J; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2019 Dec; 183():111716. PubMed ID: 31550660
[TBL] [Abstract][Full Text] [Related]
16. New Insights on Fak and Fak Inhibitors.
Brullo C; Tasso B
Curr Med Chem; 2021; 28(17):3318-3338. PubMed ID: 33143618
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
[TBL] [Abstract][Full Text] [Related]
18. FAK signaling in human cancer as a target for therapeutics.
Lee BY; Timpson P; Horvath LG; Daly RJ
Pharmacol Ther; 2015 Feb; 146():132-49. PubMed ID: 25316657
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src.
Manda S; Lee NK; Oh DC; Lee J
Molecules; 2020 Apr; 25(8):. PubMed ID: 32340152
[TBL] [Abstract][Full Text] [Related]
20. The role of focal adhesion kinase catalytic activity on the proliferation and migration of squamous cell carcinoma cells.
Serrels A; McLeod K; Canel M; Kinnaird A; Graham K; Frame MC; Brunton VG
Int J Cancer; 2012 Jul; 131(2):287-97. PubMed ID: 21823119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
